BACKGROUND: Compared with multiple daily injections (MDI), sensor-augmented pump (SAP) insulin therapy may reduce glycemic variability and oxidative stress in type 1 diabetes in a glycosylated hemoglobin (A1C)-independent manner. SUBJECTS AND METHODS: The STAR 3 study compared SAP with MDI therapy for 1 year. Week-long continuous glucose monitoring studies were conducted at baseline and 1 year for assessment of glycemic variability in both groups. Soluble CD40 ligand (CD40L), a biomarker of inflammation and thrombocyte function, was measured at baseline and 1 year. Subjects were classified according to treatment group and 1-year A1C levels (<6.5%, 6.5-6.9%, 7-7.9%, ≥8%). Glycemic parameters were compared between SAP and MDI subjects in each A1C cohort. RESULTS: At 1 year, sensor glucose values at A1C levels ≥6.5% were similar in the SAP and MDI groups. However, sensor glucose SD and coefficient of variation (CV) values were lower at A1C levels <8% among SAP than among MDI subjects; the overall between-group difference was significant for both SD (P<0.01) and CV (P=0.01). The overall mean amplitude of glycemic excursion was similar in MDI and SAP groups (P=0.23). CD40L levels fell over the course of the study in both groups, but the between-group difference was not significant (P=0.18). CD40L concentrations were unrelated to A1C, change in A1C from baseline, or glycemic variability. CONCLUSIONS: At comparable A1C levels of <8%, SAP reduced glycemic variability as measured by SD and CV compared with MDI. SAP may provide beneficial reductions in the number and severity of glycemic excursions.
BACKGROUND: Compared with multiple daily injections (MDI), sensor-augmented pump (SAP) insulin therapy may reduce glycemic variability and oxidative stress in type 1 diabetes in a glycosylated hemoglobin (A1C)-independent manner. SUBJECTS AND METHODS: The STAR 3 study compared SAP with MDI therapy for 1 year. Week-long continuous glucose monitoring studies were conducted at baseline and 1 year for assessment of glycemic variability in both groups. Soluble CD40 ligand (CD40L), a biomarker of inflammation and thrombocyte function, was measured at baseline and 1 year. Subjects were classified according to treatment group and 1-year A1C levels (<6.5%, 6.5-6.9%, 7-7.9%, ≥8%). Glycemic parameters were compared between SAP and MDI subjects in each A1C cohort. RESULTS: At 1 year, sensor glucose values at A1C levels ≥6.5% were similar in the SAP and MDI groups. However, sensor glucose SD and coefficient of variation (CV) values were lower at A1C levels <8% among SAP than among MDI subjects; the overall between-group difference was significant for both SD (P<0.01) and CV (P=0.01). The overall mean amplitude of glycemic excursion was similar in MDI and SAP groups (P=0.23). CD40L levels fell over the course of the study in both groups, but the between-group difference was not significant (P=0.18). CD40L concentrations were unrelated to A1C, change in A1C from baseline, or glycemic variability. CONCLUSIONS: At comparable A1C levels of <8%, SAP reduced glycemic variability as measured by SD and CV compared with MDI. SAP may provide beneficial reductions in the number and severity of glycemic excursions.
Authors: Stephen N Davis; Edward S Horton; Tadej Battelino; Richard R Rubin; Kevin A Schulman; William V Tamborlane Journal: Diabetes Technol Ther Date: 2010-04 Impact factor: 6.118
Authors: Richard M Bergenstal; William V Tamborlane; Andrew Ahmann; John B Buse; George Dailey; Stephen N Davis; Carol Joyce; Tim Peoples; Bruce A Perkins; John B Welsh; Steven M Willi; Michael A Wood Journal: N Engl J Med Date: 2010-06-29 Impact factor: 91.245
Authors: Maria Lajer; Inge Tarnow; Alan D Michelson; Anders Jorsal; Andrew L Frelinger; Hans-Henrik Parving; Peter Rossing; Lise Tarnow Journal: Platelets Date: 2010 Impact factor: 3.862
Authors: Rohana J Wright; David E Newby; David Stirling; Christopher A Ludlam; Ian A Macdonald; Brian M Frier Journal: Diabetes Care Date: 2010-07 Impact factor: 17.152
Authors: David Z I Cherney; James W Scholey; Etienne Sochett; Timothy J Bradley; Heather N Reich Journal: Diabetes Care Date: 2010-09-14 Impact factor: 19.112
Authors: Emma S Scott; Rachel T McGrath; Andrzej S Januszewski; Daniel Calandro; Anandwardhan A Hardikar; David N O'Neal; Gregory Fulcher; Alicia J Jenkins Journal: BMJ Open Date: 2019-12-29 Impact factor: 2.692